ZOMETA® Prostate Cancer Case Study – Reasons For ZOMETA®
Home

Videos
View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

 
European Summary of Product Characteristics
For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics
 
ZOMETA Patient Case Study: Prostate Cancer ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

ZOMETA® Prostate Cancer Patient Case Study – Dieter Dieter V.
  • Aged 61 years
  • Manages a department store
  • Coaches his grandson's football team
Medical Profile The clinical question Reasons for ZOMETA How to use ZOMETA References
Page  1 2 3

As new treatments extend survival, the threat of SREs increases for patients like Dieter

  • For patients with good performance status and metastatic disease confined to the axial skeleton, median survival is more than 4 years4
  • Without treatment, the median time to first SRE in men with bone metastases from prostate cancer is less than 11 months2


Median time to first SRE vs median survival in advanced prostate cancer2,4
ZOMETA®: Median time to first SRE vs. Survival time in prostate cancer patients
*Median survival in men with good performance status and disease confined to bone that affects the axial skeleton (treatment regimen not specified).

Page  1 2 3